Vitae to collaborate with GSK

Vitae Pharmaceuticals of Fort Washington, PA has inked a deal to collaborate with GlaxoSmithKline on developing drugs for hypertension and other cardiovascular diseases. Vitae gains an unspecified upfront payment and a deal that is worth up to $175 million for a successful development program.

"Offering significant potency and oral availability, our unique renin inhibitor compounds show promise as a breakthrough treatment for hypertension. We are very excited to work with GSK to create best-in-class medicines that make a difference and meaningfully improve patient outcomes," said Jeffrey Hatfield, CEO of Vitae.

- read this release for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.